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Abstract
Introduction
State Medicaid programs can cover tobacco cessation therapies for
millions of low-income smokers in the United States, but use of
this benefit is low and varies widely by state. This article assesses
the effects of changes in Medicaid benefit policies, general to-
bacco policies, smoking norms, and public health programs on the
use of cessation therapy among Medicaid smokers.
Methods
We used longitudinal panel analysis, using 2-way fixed effects
models, to examine the effects of changes in state policies and
characteristics on state-level use of Medicaid tobacco cessation
medications from 2010 through 2014.
Results
Medicaid policies that require patients to obtain counseling to get
medications reduced the use of cessation medications by approx-
imately one-quarter to one-third; states that cover all types of ces-
sation medications increased usage by approximately one-quarter
to one-third. Non-Medicaid policies did not have significant ef-
fects on use levels.
Conclusions
States could increase efforts to quit by developing more compre-
hensive coverage and reducing barriers to coverage. Reductions in
barriers could bolster smoking cessation rates, and the costs would
be small compared with the costs of treating smoking-related dis-
eases. Innovative initiatives to help smokers quit could improve
health and reduce health care costs.
Introduction
Efforts to reduce smoking by Medicaid beneficiaries are critical
both to improve public health and lower health care costs in the
United States, where smoking is the leading cause of preventable
illness and death (1). Medicaid’s low-income beneficiaries are ap-
proximately twice as likely to smoke as the general public, and ap-
proximately 15% of Medicaid expenditures  are  attributable to
smoking-related diseases (2). Medicaid smoking cessation initiat-
ives can lower smoking rates, reduce cardiovascular hospital ad-
missions, and generate a positive return on investment (3). Under
the Affordable Care Act (ACA), every US state now covers at
least some Medicaid tobacco cessation benefits, including medica-
tions and counseling. However, evidence indicates that only ap-
proximately 10% of Medicaid smokers receive smoking cessation
medications, and use varies widely by state (4).
To understand how to bolster smoking cessation among Medicaid
beneficiaries, we assessed why the use of smoking cessation ther-
apies is higher in some states than in others. The Centers for Dis-
ease Control and Prevention (CDC), the American Lung Associ-
ation (ALA), and many other organizations encourage coverage of
all  Food and Drug Administration  (FDA)–approved cessation
medications and counseling and elimination of barriers that might
limit access (5–7). However, these benefits may go unused if pa-
tients and physicians are unaware that they are available or are not
sufficiently  engaged  to  attempt  quitting.  Fewer  than  half  of
smokers in Medicaid-managed care plans reported that their physi-
cians offered assistance, such as medications or counseling, to quit
(8).
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We examined factors that could affect use of cessation medica-
tions  among  Medicaid  beneficiaries  in  US  states  from  2010
through  2014.  We  examined  the  effects  of  1)  state  Medicaid
smoking cessation coverage policies, such as medications covered;
2) state Medicaid limitations, such as copayments, prior authoriza-
tion,  or  requirements  for  counseling;  3)  other  state  tobacco
policies that may affect smoking, such as cigarette taxes or laws
that restrict smoking in public places; 4) state smoking norms,
based on the prevalence of smoking; and 5) other public health
programs, such as the availability of medications through state-
sponsored quitlines.
Methods
We examined state-level differences in tobacco pharmacotherapy
use in Medicaid, using data from 2010 to 2014. The outcome vari-
able was the state utilization rate: the ratio of the number of pre-
scription fills or refills paid by Medicaid for FDA-approved cessa-
tion medications divided by the estimated number of adult Medi-
caid smokers for each state and year, using methods previously de-
scribed (4). Data for state-level drug utilization are reported under
Medicaid’s drug rebate system. FDA-approved medications in-
clude nicotine replacement therapies (NRTs), including NRT gum,
patches, lozenges, sprays or inhalers, and bupropion and varenic-
line (Chantix). These medications ease withdrawal from cigarettes
and are effective, albeit imperfect, in boosting success in quitting.
Many NRT products are sold over the counter, and Medicaid will
pay for over-the-counter medications when prescribed by a clini-
cian. Bupropion may be prescribed for smoking cessation, depres-
sion, or both. Because claims data do not indicate the reason it was
prescribed, we created 2 versions of the variable: one version that
includes all FDA-approved medications including bupropion (150
mg, twice per day, which is the recommended dosage), and one
that excludes it.
There were 255 state-year observations for the 50 states and the
District of Columbia over 5 years. Our analyses considered the
possible effects of several factors that may affect the use of cessa-
tion medications by Medicaid smokers including Medicaid bene-
fit policies, other state tobacco policies, smoking norms, and pub-
lic health programs.
Medicaid benefit policies
These data were based on surveys and interviews conducted by the
ALA for CDC (9); Anne DiGilulio of ALA shared unpublished
2013  data.  The  first  variable  was  whether  the  state  Medicaid
agency covered all 3 categories of medications: NRTs, bupropion,
and varenicline. (If the state covered any NRT product, it counted
for this category. Almost all states cover NRT gum and patches,
but they vary in coverage of less widely used sprays, inhalers, and
lozenges.) We created 2 binary versions, one version indicating
that the policy applies to all Medicaid populations, including all
managed care enrollees, and an alternative version indicating that
either all populations were covered or that Medicaid managed care
organizations  (MCOs)  had  flexibility  to  determine  specific
policies. Both versions equaled 0 if there was no coverage or cov-
erage only for pregnant women. Most nonelderly, nondisabled
Medicaid adults are enrolled in MCOs. States may require that
MCOs follow uniform state-based policies but often leave some
flexibility in benefit design to MCOs. Although policies for preg-
nant women are important and the ACA requires that comprehens-
ive cessation services be available for them, our data included
pregnant women as part of total utilization. Data about policies
only for pregnant women, who are a small fraction of beneficiar-
ies, were not included in this analysis.
Other Medicaid policies examine restrictions on use of cessation
medications: whether the state charges nominal copayments, re-
quires prior authorization before prescription, limits the duration
of coverage (eg, number of months of coverage), or permits med-
ications only if counseling is also received. Medicaid cannot re-
quire cost-sharing for most children and pregnant women (10)
and, under the ACA, should cover tobacco cessation for adults en-
rolled under Medicaid expansions without cost-sharing. For each
policy, we developed binary variables that indicated whether the
state had the restriction for all populations (except those with man-
datory exclusions, such as cost-sharing exclusions). A variant of
the binary variable also included states in which policies could
vary for MCOs.
Other state tobacco policies, smoking norms, and
public health programs
We included the value of cigarette taxes per pack for each state in
the previous year (11). Taxes increase cigarette prices and discour-
age smoking, especially among youth (1). The second variable
was state smoke-free laws that restrict smoking in public areas,
specifically restaurants, bars, and nonhospitality workplaces (12)
(coded as 0 for no restrictions, 1 for restrictions in 1 or 2 areas,
and 2 for restrictions for all  3 areas).  Smoke-free laws are de-
signed to reduce secondhand smoke exposure, and they also sig-
nal public unacceptability of smoking.
Regional variations exist in smoking prevalence, suggesting dif-
ferences in social norms about smoking. We used 2010 through
2014 data from the Behavioral Risk Factor Surveillance System to
assess the percentage of a state’s adult population that currently
smokes each year (13).
All health agencies have quitlines, toll-free services that offer tele-
phone counseling and sometimes free or discounted medications
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(eg, a voucher that can be redeemed for NRT medications). We in-
cluded whether  quitlines  offer  free  or  discounted medications
(NRTs, bupropion, or varenicline) (14). Most quitlines offer NRT
gum or patches; few offer bupropion or varenicline. The National
Cancer Institute offers a national quitline, and some insurers may
also offer quitlines. However, our models included data for the
state quitlines only. (The federal quitline does not offer medica-
tions, but it may refer a caller to a state quitline.)
Analytic strategy
We used longitudinal panel estimation methods to conduct fixed-
effects regression models of how changes in policies affect use of
cessation medications, controlling for both state-level and year-re-
lated effects. The general model is equivalent to:
Ust = β0 + βXst + βSt + βT + εst
where  Ust  is  the  utilization  rate  (prescriptions  per  Medicaid
smoker) in state S and year T, Xst is a vector of independent vari-
ables in each state and year, St is a time-invariant dummy for each
state, T is the year, βs are the estimated coefficients and εst is the
residual.  Fixed-effects  models,  compared with random-effects
models, are appropriate because the data include all states, not a
sample. We used robust standard errors with Huber-White estimat-
ors to adjust for heteroscedasticity.
We tested the effects of policies, both single and multiple policies,
on medication utilization rates, using 2-way fixed effects to con-
trol for state and year. Controlling for each state nets out the ef-
fects of unmeasured state characteristics — such as racial, educa-
tional, or age composition or region or status as a tobacco-produ-
cing state — which change very little over the years but that may
also be associated with smoking or cessation behaviors on a cross-
sectional basis. Controlling for year effects limits the effects of na-
tional trends, such as changes in federal implementation of the
ACA or the Family Smoking Prevention and Tobacco Control Act
or changes in the nontax prices of cigarettes.
Our analyses treated all states as having equal weight. We con-
sidered weighting by the number of Medicaid smokers in each
state but decided against it, because it would let results from 2 lar-
ger states (New York and California) have weight equal to 28
smaller states. Significance was set at P < .10.
Results
Table 1 summarizes trends in relevant factors, presenting data for
the first and last years, 2010 and 2014. The mean use of Medicaid
tobacco cessation medication changed little nationally, although
state levels varied widely. From 2010 to 2014, there were modest
increases in the percentage of states that covered all categories of
cessation medications, with smoke-free laws, and whose quitlines
offered free or discounted medications. Mean cigarette taxes rose,
restrictions on Medicaid cessation coverage policies became less
common, and fewer states required copayments or counseling. In
models testing individual policy variables, only 2 variables were
significant; requiring counseling to get medications had a negat-
ive effect on use (P = .02), and whether the state covered all types
of medications increased use (P = .04) (data not shown). No signi-
ficant results were found for the other variables.
We used 4 multivariate  models to examine the effects of changes
in state policies and characteristics on state-level use of Medicaid
tobacco  cessation  medications.  Model  1  examines  Medicaid
policies that apply uniformly for all populations. Model 2 loosens
criteria to include states in which MCOs can vary policies, as well
as states with uniform policies. Even when MCOs have flexibility,
their policies are often the same as state fee-for-service policies
(15). We used 2 additional models (Models 3 and 4) to examine
Medicaid utilization rates for tobacco cessation medications ex-
cluding bupropion and including only NRTs and varenicline. Be-
cause it is uncertain if bupropion was prescribed for smoking ces-
sation or not, its inclusion might obscure the effect of smoking-re-
lated policies. These models are more conservative because they
only  include  medications  for  which  smoking  cessation  is  the
primary indication. Model 3 focuses on policies consistent for all
populations, while Model 4 also includes policies that may vary
across MCOs.
Table 2 presents the results of Models 1 and 2 in which the de-
pendent variable is the state utilization rate for all FDA-approved
medications in a year. In both models, requiring counseling to get
cessation  medications  reduced  utilization  rates  (coefficient  =
−0.044 for Model 1; coefficient = −0.057 for Model 2; both P <
.01). Given that the mean cessation utilization rate was 0.189 fills/
refills per smoker in 2014, these policies have an average effect of
reducing  utilization  by  23% to  30%,  controlling  for  all  other
factors. Covering all cessation medications was marginally associ-
ated with higher utilization (P = .051 in Model 1, P = .102 in Mod-
el 2), suggesting increases of approximately 24% to 34%. Despite
the uncertainty of how completely the MCOs covered or did not
cover benefits, the estimated coefficients are generally much lar-
ger in Model 2 than Model 1, suggesting that Model 2 captures ef-
fects for policies that affect the large share of beneficiaries in man-
aged care, while Model 1 failed to capture some of those effects.
Table 3 presents the results of Models 3 and 4, which examined
Medicaid utilization rates for tobacco cessation medications, ex-
cluding bupropion and including only NRTs and varenicline. The
results were similar to those of Models 1 and 2: requiring counsel-
ing was significantly associated with a reduction in cessation util-
ization, and coverage of all types of cessation medications was as-
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sociated with higher utilization. The results of Model 4 may be the
best specified of all 4 models; the coefficients were larger than
those in Model 3, indicating that it captured effects from managed
care populations. It has the highest within-R2 of all 4 models, in-
dicating the best fit of the effect of policy changes, controlling for
state- and time-invariant measures.
Discussion
This analysis is the first to identify that requiring counseling to get
cessation medications sharply lowers their use. Previous research
found that quitting can be more successful when patients use both
counseling and medications, although either alone are also effect-
ive (16,17). Greene et al found that states with Medicaid policies
permitting both counseling and pharmacotherapy had more quit at-
tempts and successful quit attempts (18). Medicaid agencies may
have sought to be helpful by requiring counseling to ensure that
patients get a stronger combination of interventions. However, the
policy appears to have unintended consequences of reducing med-
ication use by about one-quarter to one-third. Moreover, counsel-
ing may be uncommon in Medicaid. For example, in Arkansas
only 23% of Medicaid patients who received tobacco cessation be-
nefits  received  counseling  (19).  State  Medicaid  agencies  and
MCOs should  consider  recommending that  patients  seek both
medications and counseling, but not requiring one to get the other.
Broader Medicaid coverage of FDA-approved medications ap-
peared to be weakly associated with greater use of medications.
Guidelines, including the federal Healthy People 2020 objectives,
have recommended comprehensive Medicaid coverage of evid-
ence-based therapy in all states (20). These findings show that
broader coverage stimulates greater cessation efforts.  Offering
more choices can enhance the demand for medications and in-
creases the likelihood of finding medications meeting patients’
needs or clinician’s judgment. NRTs and bupropion are relatively
inexpensive medications. Though varenicline is more expensive, it
is  not  a  high-cost  drug,  particularly  because  it  is  usually  pre-
scribed for brief periods, and research indicates that it is more ef-
fective for quitting (21). The total amount Medicaid spends on to-
bacco cessation medications is well below 1% of the cost to Medi-
caid of smoking-related diseases (4); Medicaid programs should
not be attempting to save money in this area.
In this analysis, nominal copayments were not related to utiliza-
tion, in contrast to findings of earlier research. One study found
that Medicaid copayments were associated with fewer successful
quit attempts (11), and another found that Medicaid copayments
diminished the extent to which postpartum women fill their pre-
scriptions (22). A broad literature indicates that copayments lower
use of preventive health services, such as the use of drugs for hy-
pertension or diabetes (23). Perhaps copayments have little effect
in reducing use of tobacco cessation medications because those
seeking help are motivated to quit and the duration of use is usu-
ally brief (2 or 3 months); therefore, the out-of-pocket costs may
be small relative to the expected benefit.
Nonetheless, many organizations recommend against Medicaid
policies such as copayments, prior authorization, and limits of dur-
ation of benefits that could restrict access to cessation medications
(5–7). Although the analyses did not result in significant effects of
these policies, common sense suggests that they could limit ac-
cess for some, and there is no compelling reason for states to ad-
opt or retain restrictive policies, given the low cost of tobacco ces-
sation therapy.
The lack of effect of cigarette taxes or smoke-free laws was sur-
prising. Previous research has consistently found that these are 2
of the most effective strategies to reduce smoking (1). One pos-
sible explanation could be that taxes and smoke-free policies could
primarily affect initiation or prevalence of smoking, while our
study is measuring quit attempts among those who are already
smoking. An earlier study also failed to find a significant relation-
ship between state cigarette taxes and Medicaid quit attempts (24).
Nonetheless, it seems logical that higher taxes would persuade
more low-income Medicaid beneficiaries to try to quit to ease fin-
ancial burdens. Many people who may be affected by proposed
federal regulations to restrict smoking in public housing (25) will
be Medicaid beneficiaries, and efforts to facilitate cessation among
public housing clients will be needed.
The  study  has  several  limitations.  We  examined  2  potential
sources of error — measurement of Medicaid policies (all popula-
tions vs all populations plus managed care variation) and of to-
bacco cessation medications (with and without bupropion) — us-
ing alternative specifications and found consistent results.  We
were concerned that medications paid by Medicaid may exclude
some Medicaid beneficiaries who get medications through pro-
grams such as quitlines. However, because quitline variables were
not significant, our measures do not appear to be biased. There
may be additional measurement error because of potential prob-
lems in state reports of drug utilization or because of our methods
of estimating the number of Medicaid smokers in each year. Fi-
nally, the unit of analysis was the state rather than the individual
or community. We plan to conduct individual-level models to ex-
amine outcomes, such as quit attempts, but could only exploit the
analytic benefits of panel models in controlling for unmeasured
state- or year-related characteristics with state-level data.
Although these analyses examined the effects  of  certain well-
defined policies and factors, a shortcoming was that we could not
examine other hard-to-measure policies such as state, local,  or
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managed care initiatives to bolster Medicaid tobacco cessation,
whether through communications to the public or to clinicians, or
federal campaigns offered across the country. For example, Mas-
sachusetts initiated a campaign, developed by the state health and
Medicaid agencies, which led to lower smoking prevalence, re-
duced hospitalizations, and Medicaid savings (3,26). Other innov-
ative state initiatives have been documented (27). However, the di-
verse nature of these initiatives made counting and classification
difficult. A multiyear study in Arkansas found that Medicaid cov-
erage of tobacco cessation increased utilization, but the effects
waned over time; the authors concluded that other types of efforts
are needed to continue to motivate smokers and to limit barriers to
use of cessation therapies (19).
A methodological strength of this study is that longitudinal panel
analysis offers stronger evidence of the causal impact of Medicaid
policies on cessation utilization than do simpler cross-sectional
studies. Two-way fixed effects models measure how changes in
state policies or characteristics lead to changes in medication use,
netting out effects of unmeasured state characteristics and secular
trends. Also, our approach examined an array of policy and social
factors, within and outside of Medicaid, that might affect the ex-
tent to which Medicaid beneficiaries try to quit smoking.
The ultimate challenge is to empower patients and providers to in-
crease awareness of cessation benefits and to enhance motivation
and supports to undertake the difficult challenge of quitting, to im-
prove health and to reduce health care costs. Quit attempts often
end in relapses to smoking, and innovative strategies are needed to
attain long-term success. Medicaid covers tens of millions of high-
risk,  low-income Americans,  and Medicaid expansions are in-
creasing coverage of low-income smokers. The cost of smoking
cessation treatments is minute compared with the cost of smoking-
related diseases in Medicaid. Stronger efforts can both improve
health and save money. An important first  step is for states to
broaden Medicaid coverage of all approved medications and elim-
inate barriers impeding access and utilization. The long-term chal-
lenge will be for Medicaid to collaborate with public health agen-
cies, managed care plans, health systems, and clinicians to devel-
op and implement more effective strategies to help smokers to quit
and to monitor the effectiveness of these efforts.
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Tables
Table 1. Summary Data for Key Variables Among States, Use of Tobacco Cessation Medications Among Medicaid Smokers, United States, 2010 and 2014
Variable
Value (n = 51)
2010 2014
Medicaid smoking cessation utilization rate, mean (SD)
Annual fills or refills (all categories), per Medicaid smoker 0.192 (0.133) 0.189 (0.096)
Annual fills or refills (excluding bupropion), per Medicaid smoker 0.089 (0.090) 0.087 (0.063)
Adults who are current smokers, mean % (SD) 17.9 (3.4) 18.5 (3.5)
Prior year cigarette taxes per pack, mean $ (SD) 1.29 (0.80) 1.49 (0.95)
Percentage of states in which Medicaid . . .
Covers all categories of cessation medications, all populations 62.8 74.5
Covers all categories of cessation medications or permits variation across managed care
organizations
86.3 89.0
Requires copayments 54.9 47.1
Requires prior authorization 41.2 41.2
Limits duration of benefits 47.1 47.1
Requires counseling to receive cessation medications 31.4 23.5
State smoke-free laws, % of areas restricted
None 29.4 27.5
1 or 2 27.5 23.5
3 43.1 49.0
State quitline offers free or discounted medications, % 76.5 90.2
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Table 2. Two-Way Fixed Effects Regression Models of Factors Affecting Utilization Rates of All Types of Tobacco Cessation Medications Among Medicaid Smokers (n
= 255), United States, 2010–2014
State Variable
Model 1: Medicaid Policies,
All Populations
Model 2: Medicaid Policies, All Populations,
Varies by Managed Care Plan
Coefficient (Standard Error)
Medicaid policies
Covers all types of medications 0.045 (0.022)a 0.065 (0.039)
Requires copayments 0.013 (0.027) 0.002 (0.034)
Requires prior authorization 0.014 (0.016) 0.023 (0.018)
Limits duration of benefits −0.001 (0.011) 0.007 (0.018)
Requires counseling −0.044 (0.016)b −0.057 (0.017)b
Other tobacco policies
Prior year cigarette taxes 0.009 (0.019) 0.003 (0.017)
No. of smoke-free restrictions 0.015 (0.023) 0.031 (0.032)
Social norms: % of adults currently smoking −0.006 (0.005) −0.006 (0.005)
Public health programs: quitline offers medications −0.012 (0.020) −0.004 (0.020)
R2
Within 0.165 0.159
Between 0.353 0.324
Total 0.323 0.298
a P < .10.
b P < .01
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Table 3. Two-Way Fixed Effects Regression Models of Factors Affecting Utilization Rates of Nicotine Replacement Therapies and Varenicline, Excluding Bupropion,
Among Medicaid Smokers, United States, 2010–2014
State Variables
Model 3: Medicaid Policies,
All Populations
Model 4: Medicaid Policies, All Populations,
Varies by Managed Care Plan
Coefficient (Standard Error)
Medicaid policies
Covers all types of medications 0.038 (0.019)a 0.070 (0.032)b
Requires copayments 0.020 (0.023) 0.013 (0.028)
Requires prior authorization 0.017 (0.013) 0.015 (0.013)
Limits duration of benefits −0.001 (0.009) 0.003 (0.014)
Requires counseling −0.043 (0.014)c −0.045 (0.014)c
Other tobacco policies
Prior year cigarette taxes 0.005 (0.015) 0.002 (0.014)
No. of smoke-free restrictions 0.009 (0.015) 0.025 (0.024)
Social norms: % of adults currently smoking −0.002 (0.003) −0.003 (0.003)
Public health programs: quitline offers medications −0.011 (0.013) −0.003 (0.014)
R2
Within 0.198 0.204
Between 0.369 0.340
Total 0.333 0.311
a P < .10.
b P < .05.
c P < .01
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